Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Osteosarcoma Market Dynamics Expected to Grow with a CAGR of 5.70% Owing to Robust Pipeline and an Increase in Incidence for the Study period 2017-30, estimates DelveInsight

DelveInsight Logo

News provided by

DelveInsight Business Research, LLP

Nov 10, 2020, 07:30 ET

Share this article

Share toX

Share this article

Share toX

LAS VEGAS, Nov. 10, 2020 /PRNewswire/ -- The increase in the Osteosarcoma market can be attributed to a number of factors, including a number of potential drug launches in the Osteosarcoma space, improved diagnosis, rising demand for effective therapies, an increase in the incidence of Osteosarcoma, robust pipeline, and advances in medical science that have led to informed genomic pathways and a better understanding of Osteosarcoma. 

Osteosarcoma Market Report's some highlights: 

  • The United States accounted for approximately 52% of all incident cases of OS in the 7MM (the US, EU5 (the UK, Germany, Italy, France, and Spain) and Japan) in 2017.
  • The most widely used chemotherapeutic drugs such as cisplatin, doxorubicin, ifosfamide, and high-dose methotrexate with leucovorin calcium rescue (HDMTX), or a combination of these, results in approximately 60–70% increase in the overall survival.
  • The US accounts for the highest Osteosarcoma market share in the 7MM.
  • There are five emerging therapies that are expected to launch during the forecast period (2020-2030). These include Lenvatinib (Eisai Limited), Regorafenib (Bayer), Cabozantinib S-malate (Exelixis), Pazopanib Hydrochloride and Topotecan Hydrochloride (GSK), Bempegaldesleukin (NKTR-214) Plus Nivolumab (Nektar therapeutics).
  • Cabozantinib S-malate (Exelixis) is expected to get launched in 2023, will be able to add USD 4.45 million upon launch to the Osteoblastoma market in the 7MM. 

Download sample pages to gain more information@ Osteosarcoma market sample 

Osteosarcoma Epidemiological Analysis 

Osteosarcoma is a rare, high-grade solid tumor of mesenchymal origins. The tumor is more prevalent in males as compared to females. DelveInsight estimated the total Osteosarcoma incident population in the 7MM to be 2212 in 2019, with the US accounting for the majority of the incident cases in the 7MM. The increasing incidence shall positively contribute to the growth of the Osteosarcoma market.

DelveInsight's Osteosarcoma market report offers epidemiological analysis (3 year-historical and 11 year-forecasted) segmented into: 

  • Total Osteosarcoma Incident Cases in the 7MM 
  • Gender-specific Osteosarcoma Incident Cases in the 7MM 
  • Age-specific Osteosarcoma Incident Cases in the 7MM 
  • Subtypes specific Osteosarcoma Incident Cases in the 7MM 
  • Site-specific Osteosarcoma Incident Cases in the 7MM 
  • Stage-specific Osteosarcoma Incident Cases in the 7MM

Osteosarcoma Treatment Market Analysis 

The current Osteosarcoma treatment market constitutes conventional surgical resection of the tumor in concomitant with radiation therapy and chemotherapies. The localized Osteosarcoma is primarily treated with surgeries; however, around a quarter of the bone cancers, including Osteosarcoma, are diagnosed at later stages, after they have already metastasized to distant organs. Lung metastasis is generally common and has a poor prognosis. The commercially available chemotherapeutic drugs in the Osteosarcoma treatment market involve cisplatin (DDP), doxorubicin, ifosfamide (IFO), and high-dose methotrexate (MTX) with leucovorin calcium rescue (HDMTX). In addition to chemotherapeutic agents, the Osteosarcoma market has approved medication to address the side effects of the chemotherapeutic agents. Khapzory, a successor of Fusilev, both the drugs are indicated to reduce the effects of high-dose methotrexate therapy and are the products of Spectrum Pharmaceuticals. Further, there is Mepact, an immunomodulator of Takeda. However, the drug is only approved by the EMA. The FDA owing to concerns regarding safety and efficacy did not recommend it in the US. 

Even after refined advancements in cancer treatment, the Osteosarcoma market has not seen any approvals or launch of novel therapies in the past 40 years. Multi-drug-resistance poses a significant problem with the present chemotherapies. The treatment approaches present offer no relief to patients with relapsed or refractory Osteosarcoma. The second-line therapies appear quite upsetting, and there is no available therapy to cease the progression of the tumor. There are several unmet needs in the Osteosarcoma treatment market that require urgent attention. 

To address the unmet needs, however, several companies are investigating their agents in different stages of clinical trials. The present goal of the Osteosarcoma market is to offer a therapy that is clinically safe, efficient, and the potential to halt the tumor progression, prevent metastasis of the tumor, and provide long-term benefits with minimum toxicity. 

Know more about the Osteosarcoma Report offerings@ Osteosarcoma Market Insights

Osteosarcoma Market Analysis

Several key pharma companies are working to propel the Osteosarcoma market. The companies and academics are tirelessly assessing the challenges present in the treatment of Osteosarcoma and seeking opportunities to influence Osteosarcoma R&D. Key pharma companies working in the Osteosarcoma market are Eisai Limited, Bayer, Exelixis, Nektar Therapeutics, Y-mAbs Therapeutics, GlaxoSmithKline, Novartis, Aadi Bioscience, Eleison Pharmaceuticals, Aurora biopharma, BioAtla, Iovance Biotherapeutics, Bristol-Myers Squibb, Cellestia Biotech among others. 

Out of all the emerging therapies, five including, Lenvatinib (Eisai Limited), Regorafenib (Bayer), Cabozantinib S-malate (Exelixis), Pazopanib Hydrochloride and Topotecan Hydrochloride (GSK), Bempegaldesleukin (NKTR-214) Plus Nivolumab (Nektar therapeutics), are anticipated to be launch in the forecast period 2020-30. DelveInsight estimates that of all the therapies in the Osteoblastoma pipeline, Cabozantinib S-malate (Exelixis), expected to launch in 2023, will be able to add USD 4.45 million upon launch to the Osteoblastoma market in the 7MM. 

Although the future of the Osteosarcoma market looks promising, there can be hidden snags in the growth of the market in the form of clinical enrollment due to the rarity of the tumor. Nevertheless, several pipeline therapies are set to be launched in the foreseeable future, and the rising incidence of Osteosarcoma is expected to fuel the market growth. Further, the dedication of academia to increase R&D in the domain shall present a clearer picture of the Osteosarcoma pathogenesis. The proactive approach of the private pharma and biotech industry is expected to accelerate the growth of the Osteosarcoma market size to multiple folds for the study period 2017-30. 

Osteosarcoma Marketed Therapies 

  • Mepact (Mifamurtide): Takeda
  • Khapzory (levoleucovorin): Acrotech Biopharma

Osteosarcoma Pipeline Therapies 

  • Regorafenib: Bayer
  • Cabozantinib S-malate: Exelixis
  • Bempegaldesleukin: Nektar Therapeutics
  • Lenvatinib in Combination with Ifosfamide and Etoposide: Eisai
  • Danyelza: Y-mAbs Therapeutics
  • Pazopanib Hydrochloride and Topotecan Hydrochloride: GlaxoSmithKline/Novartis
  • Nab-rapamycin with Nivolumab: Aadi Bioscience
  • Pepinemab: Vaccinex, Inc.
  • Nivolumab With or Without Ipilimumab: National Cancer Institute/Assaf-Harofeh Medical
  • Inhaled Lipid-complexed Cisplatin: Eleison Pharmaceuticals
  • Aliqopa: Bayer
  • AU101: Aurora biopharma
  • CAB-AXL-ADC (BA3011): BioAtla
  • LN-145: Iovance Biotherapeutics
  • Arfolitixorin: Isofol Medical AB
  • Opdivo: Bristol-Myers Squibb
  • CB-103: Cellestia Biotech

Scope of the Report

  • Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
  • Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
  • Markets Segmentation: By Geographies, By Therapies (Forecasted + Historical), By Line of Therapies (First-line, Second-line, and Third-line), By Stages (Metastatic and Non-Metastatic).
  • Companies Covered: Eisai Limited, Bayer, Exelixis, Nektar Therapeutics, Y-mAbs Therapeutics, GlaxoSmithKline, Novartis, Aadi Bioscience, Eleison Pharmaceuticals, Aurora biopharma, BioAtla, Iovance Biotherapeutics, Bristol-Myers Squibb, Cellestia Biotech, among others.
  • Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis.
  • Case Studies
  • KOL's Views
  • Analyst's View

Request for a Webex demo of Osteosarcoma report: https://www.delveinsight.com/report-store/osteosarcoma-market 

Table of Contents 

1

Key Insights

2

Executive Summary of Osteosarcoma

3

Osteosarcoma Market Overview at a Glance

4

Disease Background and Overview: Osteosarcoma

5

Osteosarcoma Case Reports

6

Osteosarcoma Epidemiology and Patient Population

7

The United States Osteosarcoma Epidemiology 

8

EU5 Osteosarcoma Epidemiology

9

Japan Osteosarcoma Epidemiology

10

Osteosarcoma Unmet Needs

11

Osteosarcoma Treatment 

12

Osteosarcoma Marketed Therapies

13

Osteosarcoma Emerging Therapies

14

Osteosarcoma 7 Major Market Analysis

15

Key Market Forecast Assumptions

16

7MM Market Outlook

17

EU5

18

Japan

19

Osteosarcoma Market Drivers

20

Osteosarcoma Market Barriers

21

SWOT Analysis

22

Osteosarcoma Reimbursement and Market Access

23

KOL Views

24

Appendix

25

DelveInsight Capabilities

26

Disclaimer

27

About DelveInsight

Related Reports 

Osteosarcoma - Pipeline Insights, 2020

"Osteosarcoma Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Osteosarcoma market. 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us:

Shruti Thakur 
[email protected] 
+1(919)321-6187 
www.delveinsight.com

SOURCE DelveInsight Business Research, LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight

Graves' Orbitopathy Market to Exhibit Growth at a CAGR of 19.8% During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Graves' Orbitopathy Market Insights report includes a comprehensive understanding of current treatment practices, Graves' orbitopathy...

CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight

CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight

DelveInsight's CXCR Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Surveys, Polls and Research

Surveys, Polls and Research

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.